In stock COA-35%
In stock COA DOCUMENT SLOT-35%
Metabolic ResearchSurvodutide
Dual GLP-1/glucagon receptor agonist by Boehringer Ingelheim — studied for metabolic and hepatic lipid research.
Research catalogueLaboratory-use positioning
Batch documentationBatch certificate supplied with order
Order trackingFrom payment to dispatch
Product information
CompoundSurvodutide
Presentation5mg vial
CategoryMetabolic Research
AvailabilityIn stock
Batch COACertificate supplied with order
You save €175.00 on this presentation — an extra 10% off when you pay with crypto.
For research use only. Not for human consumption, diagnostic, therapeutic or veterinary use.
Overview
Survodutide (BI 456906) is a dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim, currently in Phase 3 clinical trials for obesity and metabolic liver disease. Unlike dual GLP-1/GIP agonists, survodutide uniquely combines GLP-1 receptor agonism with glucagon receptor activation — leveraging glucagon's thermogenic and lipolytic properties. Phase 2 results demonstrated approximately 16.6% average weight loss at the highest dose after 76 weeks, with notable improvements in hepatic steatosis markers.
Mechanism of Action
Survodutide engages two complementary receptor pathways. GLP-1 receptor activation promotes satiety through hypothalamic signalling, delays gastric emptying, and enhances glucose-dependent insulin secretion. Glucagon receptor agonism — the distinguishing feature — increases hepatic energy expenditure through enhanced lipid oxidation, stimulates thermogenesis, and promotes hepatic fat mobilisation. This unique combination addresses both caloric intake (via GLP-1) and energy expenditure (via glucagon), while the GLP-1 component counterbalances glucagon's hyperglycaemic potential by maintaining insulin secretion.
Research Applications
- Dual GLP-1/glucagon receptor signalling research
- Hepatic lipid metabolism and steatosis models
- Thermogenesis and energy expenditure studies
- Metabolic liver disease pathway investigation
- Comparative dual-agonist pharmacology (GIP vs glucagon)
FREE TOOL
Reconstitution calculator
Enter your reconstitution to get the draw volume for Survodutide.
Concentration2.50 mg/ml
Draw volume0.100 ml
On the syringe10.0 units
Doses per vial20
10units
Pull the plunger to 10.0 units on a 1 ml U‑100 syringe0.100 ml · 2.50 mg/ml · 20 doses per vial
Concentration = peptide mass ÷ water volume. Unit readings assume U-100 insulin syringes, graduated 100 units per millilitre. For laboratory calculation only — not dosing guidance.